Utilization of programmed death-ligand 1 (PD-L1) expression or tumor mutation burden (TMB) of the cancer cells to predict the clinical response of NSCLC to anti-PD-1 or anti-PD-L1 treatment is also not as accurate as expected [8]. Here, CD274 is linked to non-small cell lung carcinoma.